Cefazolin for Methicillin-Sensitive Staphylococcus aureus Infections

Evidence Supporting Cefazolin for MSSA

• The Infectious Diseases Society of America recommends cefazolin as an appropriate treatment option for pyomyositis caused by MSSA 1
• Many experts regularly use cefazolin for S. aureus infections instead of nafcillin due to better drug tolerability and cost, particularly for MSSA infections 2, 3
• Cefazolin is specifically listed as a reasonable alternative in patients with a well-defined history of nonanaphylactoid reactions to penicillins who have MSSA infections 4

Clinical Considerations When Using Cefazolin for MSSA

• In cases of brain abscess resulting from MSSA infective endocarditis, guidelines recommend nafcillin instead of cefazolin due to concerns about CNS penetration 2, 5
• Although cefazolin may be more susceptible to β-lactamase–mediated hydrolysis than nafcillin in laboratory testing, the clinical significance of this observation remains uncertain 6

Important Distinction Between MSSA and MRSA

• Once culture results confirm MSSA, therapy can be narrowed to cefazolin as an appropriate targeted therapy 6

Dosing and Administration

• For serious MSSA infections, cefazolin is typically administered intravenously at doses of 0.5-1g every 8 hours, with adjustments based on infection severity and renal function 1